NCI-H441 Transfection Reagent (Lung Adenocarcinoma)

Altogen Biosystems is a quality provider and research corporation for biological laboratories. Custom biological services and supplementary preclinical items include siRNA screening, cell transfection optimization, quick cell line generation, liposome encapsulation and more. Dedicated to benefiting customers with useful and excellent services, Altogen Biosystems aims to advance modern pharmaceutical technologies. Visit Altogen for a comprehensive assortment of lung cancer xenograft models and related tools for biomedical research.

NCI-H441 cells were derived from the papillary adenocarcinoma of a human male patient and constitute an epithelial cell line that is one of the foremost models researchers have for investigating the efficacy of inhalant-based cancer therapies. With delivery to the lungs much easier through airways in the human body, novel treatments may focus on delivering nucleic acids in non-cytotoxic transfection reagents to alveoli and other lung cells. NCI-H441 cells are known for doubling in population size under sixty hours, and express the major surfactant apoprotein, making them a unique environment for drug testing, lung cancer research, and siRNA screening for the development of gene therapies targeting late-stage lung cancer.

The NCI-H441 cell line was discovered in 1982, and derived from the p ericardial fluid of a   male patient suffering from papillary adenocarcinoma.  The cells express both major surfactant apoprotein (SP-A) and pulmonary surfactant protein (SP-B) with a doubling time of roughly 58 hours. The biomedical application of NCI-H441 widely ranges however its primary use is in lung cancer research. Altogen Biosystems provides a transfection reagent for NCI-H441 that optimizes the transfection efficiency.  Transfection Reagent for NCI-H441 Cells (Lung Adenocarcinoma Cells, HTB-174)